1 Min Read
Feb 15 (Reuters) - Ardelyx Inc
* Ardelyx announces successful phase 3 trial of Tenapanor for hyperphosphatemia in patients with end-stage renal disease
* Tenapanor was well-tolerated in trial
* Ardelyx-Trial results support plans to initiate 2nd phase 3 study of tenapanor for treatment of hyperphosphatemia in esrd patients on dialysis in mid-2017.
* Trial of tenapanor for hyperphosphatemia in patients with end-stage renal disease who are on dialysis met its primary endpoint Source text for Eikon: Further company coverage: (Bangalore.email@example.com)